Antifungal drugs prevent topical or invasive fungal infections (mycoses) either by stopping growth of fungi (termed fungistatic) or by killing the fungal cells (termed fungicidal). Antibiotics also prevent bacterial infections through either bacteriostatic or bactericidal mechanisms. These microorganisms successfully develop resistance against conventional drugs that are designed to kill or stop them from multiplying. When a fungus no longer responds to antifungal drug treatments and continues to grow, this is known as antifungal drug resistance. Bacteria have an amazing capacity to become resistant to antibiotic action as well, and the effectiveness of the scarce antifungal arsenal is jeopardised by this antibiotic resistance, which poses a severe threat to public health.
Integrating artificial intelligence (AI) with nanotechnology has revolutionized immunological research by enabling the precise design, optimization, and functionalization of nanoparticles. AI-generated nanoparticles (AIGNPs) exhibit enhanced capabilities in vaccine development, cancer immunotherapy, and autoimmune disease treatment through improved antigen delivery, targeted drug release, and immune modulation. AI-powered models help researchers quickly analyze how nanoparticles behave, interact with immune cells, and determine their compatibility with the body. This speeds up the development of new treatments. But there are still a lot of obstacles. Obstacles still include strict legal requirements, moral dilemmas, and the requirement for extensive experimental support. AI-generated nanoparticles have infinite therapeutic potential once these obstacles are removed. Resolving these issues could result in more precise and personalized cancer immunotherapy, which would revolutionize patient care.
5 June 2020 in International Journal of Science and Research (IJSR)